RxDoctor Payments DataLook up a doctor →

James Herrington, MD

Hematology & Oncology · Hattiesburg, MSNPI 1730192907

Payments from drug & device makers

$14,253in general payments, 2019–2025

Across 741 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$803
  • Novartis$703
  • AstraZeneca$702
  • Incyte Corporation$691
  • Genentech USA, Inc.$679
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$13,65396%
  • Education$6004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)63$1,167
E.r. Squibb & Sons, L.L.C.42$803
Novartis40$703
AstraZeneca(2 entities)37$702
Incyte Corporation34$691
Genentech USA, Inc.37$679
Pfizer42$651
Seagen Inc.21$564
Daiichi Sankyo Inc.20$474
Astellas Pharma US Inc26$465
Merck21$454
Sanofi25$445
AbbVie18$367
Gilead(2 entities)20$346
Amgen18$313
GSK17$309
Bristol Myers Squibb16$309
Lilly USA, LLC11$253
Exelixis Inc.11$240
Octapharma USA, Inc.10$213
Takeda Pharmaceuticals U.S.A., Inc.11$208
Eisai Inc.10$188
Coherus Oncology, Inc.10$185
Jazz Pharmaceuticals Inc.8$175
Bayer10$166
Stemline Therapeutics Inc.7$163
Regeneron Healthcare Solutions, Inc.7$158
Beigene USA, Inc.8$158
Puma Biotechnology, Inc.10$140
Blueprint Medicines Corporation6$140
EMD Serono, Inc.7$119
Karyopharm Therapeutics Inc.4$116
ADC Therapeutics America, Inc.4$102
ASD Specialty Healthcare, LLC2$98
Morphosys, US Inc.6$93
Ipsen Biopharmaceuticals, Inc5$91
Beone Medicines USA, Inc.4$89
Deciphera Pharmaceuticals Inc.4$89
Pharmacyclics LLC, An Abbvie Company5$89
Tersera Therapeutics LLC3$88
Genmab U.S., Inc.5$87
Pharmacosmos Therapeutics Inc.5$82
Taiho Oncology, Inc.4$82
G1 Therapeutics, Inc.5$78
Boehringer Ingelheim4$71
Springworks Therapeutics, Inc.4$68
Fresenius Kabi USA, LLC3$65
Tesaro, Inc.3$59
Rigel Pharmaceuticals, Inc.4$58
Spectrum Pharmaceuticals Inc.2$53
Sumitomo Pharma America, Inc.1$52
Sanofi-aventis U.S. LLC3$49
Adaptive Biotechnologies Corporation2$47
Pharmaessentia USA Corporation2$45
Apellis Pharmaceuticals, Inc.3$45
Verastem, Inc.3$42
AVEO Pharmaceuticals, Inc.2$39
Lexicon Pharmaceuticals, Inc.3$38
Janssen Scientific Affairs, LLC2$38
Sobi, Inc2$35

How this compares

$14,253 in reported general payments places this provider in the 50th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$3,369,633
Medicare patients
519
Services billed
136,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide70$1,617,794
Lenalidomide55$885,911
PomalystPomalidomide21$478,238
JakafiRuxolitinib Phosphate13$344,374
SprycelDasatinib12$224,612
BrukinsaZanubrutinib11$155,782
EliquisApixaban26$14,980
XareltoRivaroxaban11$9,323
Enoxaparin Sodium12$7,074
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen186$5,512
Anastrozole326$3,333
Morphine Sulfate ErMorphine Sulfate35$2,210
Megestrol Acetate38$1,895
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen32$1,085
Hydroxyurea74$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$309$1,617,79470 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$803$702,85133 claims
Incyte CorporationJakafi$691$344,37413 claims
Beigene USA, Inc.Brukinsa$158$155,78211 claims
PfizerEliquis$651$14,98026 claims
Johnson & JohnsonXarelto$1,167$9,32311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 57 hematology & oncology providers in Mississippi.

Other hematology & oncology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →